SenesTech reported Q3 2024 revenues of $482,000, a 34% increase from $360,000 in Q3 2023, primarily driven by the successful launch of its Evolve product line. Evolve, launched in January 2024, contributed approximately 68% of quarterly revenue at $330,000. Gross profit margin improved to 65.4% from 48.8% year-over-year due to favorable product mix.The company reduced its net loss to $1.5 million in Q3 2024 from $1.9 million in Q3 2023, reflecting lower operating expenses of $1.9 million compared to $2.1 million. Cost reductions came mainly from decreased personnel expenses, professional fees, and insurance costs. Research and development expenses increased 19% to $451,000 due to expanded facilities and development efforts.As of September 30, 2024, SenesTech had cash and equivalents of $2.5 million, which management expects will fund operations for at least four months. The company noted additional financing will be needed before achieving anticipated revenue and margin targets. During Q3, the company raised $2.0 million through warrant exercises to support ongoing commercialization efforts.

SenesTech reported Q3 2024 revenues of $482,000, a 34% increase from $360,000 in Q3 2023, primarily driven by the successful launch of its Evolve product line. Evolve, launched in January 2024, contributed approximately 68% of quarterly revenue at $330,000. Gross profit margin improved to 65.4% from 48.8% year-over-year due to favorable product mix.The company reduced its net loss to $1.5 million in Q3 2024 from $1.9 million in Q3 2023, reflecting lower operating expenses of $1.9 million compared to $2.1 million. Cost reductions came mainly from decreased personnel expenses, professional fees, and insurance costs. Research and development expenses increased 19% to $451,000 due to expanded facilities and development efforts.As of September 30, 2024, SenesTech had cash and equivalents of $2.5 million, which management expects will fund operations for at least four months. The company noted additional financing will be needed before achieving anticipated revenue and margin targets. During Q3, the company raised $2.0 million through warrant exercises to support ongoing commercialization efforts.